Vascular proteomics

Methods in Molecular Biology

Volumn 1000, Issue , 2013, Pages 1-20

  Barderas, Maria G ^a   Vivanco, Fernando ^b,c   Alvarez Llamas, Gloria ^b  

^a HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

^b UAM)   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Atherosclerosis; Biomarkers; Metabolomics; MS imaging; Plasma; Secretome; Serum; Systems biology; Urine; Vascular proteomics

Indexed keywords

BIOLOGICAL MARKER; PROTEOME; SECRETOME; UNCLASSIFIED DRUG;

ARTERY CALCIFICATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY FLUID; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; DISEASE MARKER; ENDOTHELIUM CELL; HEART INFARCTION; HUMAN; MASS SPECTROMETRY; METABOLOMICS; MOLECULAR IMAGING; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEOMICS; SYSTEMS BIOLOGY; TISSUES; VASCULAR ENDOTHELIUM; ANIMAL; BLOOD VESSEL; CARDIOVASCULAR DISEASES; METABOLISM; PATHOLOGY; PROCEDURES; METHODOLOGY; REVIEW;

ANIMALS; BLOOD VESSELS; CARDIOVASCULAR DISEASES; HUMANS; MASS SPECTROMETRY; METABOLOMICS; PROTEOMICS; SYSTEMS BIOLOGY;

EID: 84891673509     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-405-0_1     Document Type: Article

References (82)

1. Davignon J, Ganz P (2004) Role of endothelial dysfunction in atherosclerosis. Circulation 109:III27-III32
2. Alvarez-Llamas G, de la Cuesta F, Barderas MG, Darde V, Padial LR, Vivanco F (2008) Recent advances in atherosclerosis-based proteomics: New biomarkers and a future perspective. Expert Rev Proteomics 5:679-691
3. Biomarkers De fi nitions Working Group (2001) Biomarkers and surrogate endpoints: Preferred de fi nitions and conceptual framework. Clin Pharmacol Ther 69:89-95
4. Finley Austin MJ, Babiss L (2006) Commentary: where and how could biomarkers be used in 2016. AAPS J 8:E185-E189
5. Sturgeon C, Hill R, Hortin GL, Thompson D (2010) Taking a new biomarker into routine use - a perspective from the routine clinical biochemistry laboratory. Proteomics Clin Appl 4:892-903
6. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847
7. Apple FS, Collinson PO (2012) IFCC task force on clinical applications of cardiac biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 58:54-61
8. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D et al (2009) B-type natriuretic peptides and cardiovascular risk: Systematic review and meta-analysis of 40 prospective studies. Circulation 120:2177-2187
9. Nicholson JK, Lindon LC (2008) Systems biology: Metabolomics. Nature 455:1054-1056
10. Wike RA, Mereedu RK, Moore JH (2008) The pathway less traveled: Moving from candidate genes to candidate pathways in the analysis of genome-wide data from large scala pharmacogenetic association studies. Curr Pharmacogenomics Person Med 6:150-159
11. Ozdemir V, Suarez-Kurtz G, Stenne E, Somoggyi A, Kayaalp O, Kolker E (2008) Risk assessment and communication tools for genotype associations with multifactorial phenotypes: The concept of "edge effect" and cultivating an ethical bridge between omics innovations and society. J Integr Biol 13:43-62
12. Beer LA, Tang H, Barnhart KT, Speicher DW (2011) Plasma biomarker discovery using 3D protein pro fi ling coupled with label-free quantitation methods. Mol Biol 728:3-27
13. Thakur SS, Geiger T, Chatterjee B, Bandilla P, Fröhlich F, Cox J, Mann M (2011) Deep and highly sensitive proteome coverage by LC-MS/MS without prefractionation. Mol Cell Proteomics 10:M110.003699
14. Mischak H, Coon JJ, Novak J, Weissinger EM, Schanstra J, Dominiczak AF (2009) Capillary electrophoresis - mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: An update of recent developments. Mass Spectrom Rev 28:703-724
15. Barderas MG, Laborde CM, Posada M, de la Cuesta F, Zubiri I, Vivanco F, Alvarez-Llamas G (2011) Metabolomic pro fi ling for identi fi cation of novel potential biomarkers in cardiovascular diseases. J Biomed Biotechnol doi: 10.1155/2011/790132.
16. Rhee EP, Gerszten RE (2012) Metabolomics and cardiovascular biomarker discovery. Clin Chem 58:139-147
17. McDonnell LA, Heeren RMA (2007) Imaging mass spectrometry. Mass Spectrom Rev 26: 606-643
18. Wang J, Balu N, Canton G, Yuan C (2010) Imaging biomarkers of cardiovascular disease. J Magn Reson Imaging 32:502-515
19. Lange V, Picotti P, Domon B, Aebersold R (2008) Selected reaction monitoring for quantitative proteomics: A tutorial. Mol Syst Biol 4:222
20. Veenstra TD, Conrads TP, Hood BL, Avellino AM, Ellenbogen RG (2005) Biomarkers: Mining the bio fl uid proteome. Mol Cell Proteomics 4:409-418
21. Anderson NL (2005) Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 563:23-60
22. Wang YY, Cheng P, Chan DW (2003) A simple af fi nity spin tube fi lter method for removing high-abundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis. Proteomics 3:243-248
23. Bjorhall K, Miliotis T, Davidsson P (2005) Interest of major serum protein removal for surface-enhanced laser desorption/ionization - time of fl ight (SELDI-TOF) proteomic blood pro fi ling. Proteomics 5:307-317
24. Seam N, Gonzales DA, Kern SJ, Hortin GL, Hoehn GT, Suffredini AF (2007) Quality control of serum albumin depletion for proteomic analysis. Clin Chem 53:1915-1920
25. Thongboonkerd V, McLeish KR, Arthur JM, Kelin JB (2002) Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 62:1461-1469
26. Thongboonkerd V, Malasit P (2007) Renal and urinary proteomics: Current applications and challenges. Proteomics 5:1033-1042
27. Espina V et al (2008) A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 7:1998-2018
28. Emmert-Buck MR et al (1996) Laser capture microdissection. Science 274:998-1001
29. Alvarez-Llamas G et al (2007) Characterization of the human visceral adipose tissue secretome. Mol Cell Proteomics 6:589-600
30. Hocking SL et al (2010) Intrinsic depotspeci fi c differences in the secretome of adipose tissue, preadipocytes, and adipose tissuederived microvascular endothelial cells. Diabetes 59:3008-3016
31. Danesh J, Wheeler JG, Hirsch fi eld GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V (2004) C-reactive protein and other circulating markers of in fl ammation in the prediction of coronary heart disease. N Engl J Med 350:1387-1397
32. Sidney C, Smith J, Anderson JL, Cannon RO, Fadl YY, Koenig W, Libby P, Lipshultz SE, Mensah GA, Ridker PM, Rosenson R (2004) CDC/AHA Workshop on markers of in fl ammation and cardiovascular disease application to clinical and public health practice: Report from the Clinical Practice Discussion Group. Circulation 110:e550-e555
33. Mayr M, Mayr U, Chung YL, Yin X, Grif fi ths JR, Xu Q (2004) Vascular proteomics: Linking proteomic and metabolomic changes. Proteomics 4:3751-3761
34. Marian AJ, Nambi V (2004) Biomarkers of cardiac disease. Expert Rev Mol Diagn 2004(4):805-820
35. Berhane BT, Zong C, Liem DA, Huang A, Le S, Edmondson RD, Jones RC, Qiao X, Whitelegge JP, Ping P, Vondriska TM (2005) Cardiovascular-related proteins identi fi ed in human plasma by the HUPO Plasma Proteome Project pilot phase. Proteomics 5:3520-3530
36. Brea D, Sobrino T, Blanco M, Fraga M, Agulla J, Rodriguez-Yañez M, Rodriguez-Gonzalez R, Perez de la Ossa N, Leira R, Forteza J, Davalos A, Castillo J (2009) Usefulness of haptoglobin and serum amyloid A proteins as biomarkers for atherothrombotic ischemic stroke diagnoses con fi rmation. Atherosclerosis 205(2):561-567
37. Ganesh SK, Sharma Y, Dayhoff J, Fales HM, Van Eyk J, Kickler TS, Billings EM, Nabel EG (2007) Detection of venous thromboembolism by proteomic serum biomarkers. PLoS One 2(6):e544
38. Liu RX, Chen HB, Tu K, Zhao SH, Li SJ, Dai J, Li QR, Nie S, Li YX, Jia WP, Wu JR (2008) Localized-statistical quanti fi cation of human serum proteome associated with type 2 diabetes. PLoS One 3:e3224
39. Zimmerli LU, Schiffer E, Zürbig P, Good DM, Kellmann M, Mouls L, Pitt AR, Coon JJ, Schmieder RE, Peter KH, Mischak H, Kolch W, Delles C, Dominiczak AF (2008) Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics 7:290-298
40. Coon J, Zurbig P, Dakna M, Dominiczak A, Decramer S et al (2008) CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl 2:964-973
41. Von zur Muhlen C, Schiffer E, Zuerbig P, Kellmann M, Brasse M, Meert N, Vanholder RC, Dominiczak AF, Chen YC, Mischak H, Bode C, Peter K (2009) Evaluation of urine proteome pattern analysis for its potential to re fl ect coronary artery atherosclerosis in symptomatic patients. J Proteome Res 8: 335-345
42. Martinet W, Schrijvers DM, De Meyer GR, Herman AG, Kockx MM (2003) Western array analysis of human atherosclerotic plaques. Down regulation of apoptosis-linked gene Cardiovasc Res 60:259-267
43. Martinet W (2006) Western array analysis of human atherosclerotic plaques. Methods Mol Biol 357:165-178
44. Donners M, Verluyten MJ, Bouwman FG, Mariman E, Devrese B et al (2005) Proteomic analysis of differential protein expression in human atherosclerotic plaque progression. J Pathol 206:39-45
45. Slevin M, Elasbali AB, Turu M, Krupinski J, Badimon L et al (2006) Identi fi cation of differential protein expression associated with development of unstable human carotid plaques. Am J Pathol 168:1004-1021
46. Roelofsen H, Dijkstra M, Weening D, de Vries MP, Hoek A, Vonk RJ (2009) Comparison of isotope-labeled amino acid incorporation rates (CILAIR) provides a quantitative method to study tissue secretomes. Mol Cell Proteomics 8:316-324
47. Durán MC, Mas S, Martin-Ventura JL, Meilhac O, Michel JB et al (2003) Proteomic analysis of human vessels: Application to atherosclerotic plaques. Proteomics 3:973-978
48. Durán MC, Martin-Ventura JL, Mohammed S, Barderas MG, Mas S et al (2007) Atorvastatin modulates the pro fi le of proteins released by human atherosclerotic plaques. Eur J Pharmacol 562(1-2):119-129
49. Duran MC, Martín-Ventura JL, Mas S, Barderas MG, Darde V et al (2006) Characterization of the human atherome plaque secretome by proteomic analysis. Methods Mol Biol 357:141-150
50. Vivanco F, Martin-Ventura JL, Duran MC, Barderas MG, Blanco-Colio L et al (2005) Quest for novel cardiovascular biomarkers by proteomic analysis. J Proteome Res 4:1181-1191
51. Martín-Ventura JL, Duran MC, Blanco-Colio L, Meilhac O, Leclercq A et al (2004) Identi fi cation by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation 110:2216-2219
52. Martin-Ventura JL, Nicolas V, Houard X, Blanco-Colio L, Leclercq A et al (2006) Biological signi fi cance of decreased HSP27 in human atherosclerosis. Arterioscler Thromb Vasc Biol 26:1337-1343
53. de la Cuesta F, Barderas MG, Calvo E, Zubiri I, Maroto AS, Darde VM, Martin-Rojas T, Gil-Dones F, Posada-Ayala M, Tejerina T, Lopez JA, Vivanco F, Alvarez-Llamas G (2011) Secretome analysis of atherosclerotic and non-atherosclerotic arteries reveals dynamic extracellular remodeling during pathogenesis. J Proteomics 75(10): 2960-2971
54. Fiehn O, Kopka J, Dormann P, Altmann T, Trethwey R, Wilmitzer J (2000) Metabolite pro fi ling for plant functional genomics. Nat Biotechnol 18:1157-1161
55. Nicholson JK, Lindon J, Holmes E (1999) Metabolomics: Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NRM spectroscopic data. Xenobiotica 29:1181-1189
56. Dunn W, Bailey N, Johnso H (2005) Measuring the metabolome: Current analytical technologies. Analyst 130:606-625
57. Harrigan G, LaPlante R, Cosma G, Cockerell G, Goodacre R, Maddox J et al (2004) Application of high-throughput Fouriertransform infrared spectroscopy in toxicology studies: Contribution to a study on the development of an animal model for idiosyncratic toxicity. Toxicol Lett 146:197-205
58. Lenz EM, Bright J, Wilson ID, Morgan SR, Nash AF (2003) A 1H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects. J Pharm Biomed Anal 33:1103-1115
59. Musiek ES, Yin H, Milne GL, Morrow JD (2005) Recent advances in the biochemistry and clinical relevance of the isoprostane pathway. Lipids 40:987-994
60. Cho HJ, Kim JD, Lee WY, Chung BC, Choi MH (2009) Quantitative metabolic pro fi ling of 21 endogenous corticosteroids in urine by liquid chromatography-triple quadrupolemass spectrometry. Anal Chim Acta 632:101-108
61. Wang Z, Tang WH, Cho L, Brennan DM, Hazen SL (2009) Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: Potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler Thromb Vasc Biol 29:1383-1391
62. Teul J, Ruperez FJ, Garcia A, Vaysse J, Balayssac S, Gilard V et al (2009) Improving metabolite knowledge in stable atherosclerosis patients by association and correlation of GC-MS and 1H NMR fi ngerprints. J Proteome Res 8: 5580-5589
63. Mayr M, Yusuf S, Weir G, Chung YL, Mayr U, Yin X et al (2008) Combined metabolomic and proteomic analysis of human atrial fi brillation. J Am Coll Cardiol 51:585-594
64. Chen X, Liu L, Palacios G, Gao J, Zhang N, Li G, Lu J, Song T, Zhang Y (2010) Plasma metabolomics reveals biomarkers of the atherosclerosis. J Sep Sci 33:2776-2783
65. Zhang F, Jia Z, Gao P, Kong H, Li X, Chen J et al (2009) Metabonomics study of atherosclerosis rats by ultra fast liquid chromatography coupled with ion trap-time of fl ight mass spectrometry. Talanta 79:836-844
66. Turer AT, Stevens RD, Bain JR, Muehlbauer MJ, van der WJ, Mathew JP et al (2009) Metabolomic pro fi ling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation 119:1736-1746
67. Zhao G, Jeoung NH, Burgess SC, Rosaaen- Stowe KA, Inagaki T, Latif S et al (2008) Overexpression of pyruvate dehydrogenase kinase 4 in heart perturbs metabolism and exacerbates calcineurin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol 294:H936-H943
68. Lewis GD, Wei R, Liu E, Yang E, Shi X, Martinovic M et al (2008) Metabolite pro fi ling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 118:3503-3512
69. Vallejo M, Garcia A, Tunon J, Garcia-Martinez D, Angulo S, Martin-Ventura JL et al (2009) Plasma fi ngerprinting with GC-MS in acute coronary syndrome. Anal Bioanal Chem 394:1517-1524
70. von Zur Muhlen C, Schiffer E, Zuerbig P, Kellmann M, Brasse M, Meert N et al (2009) Evaluation of urine proteome pattern analysis for its potential to re fl ect coronary artery atherosclerosis in symptomatic patients. J Proteome Res 8:335-345
71. Schwartz SA, Reyzer ML, Capriol RM (2003) Direct tissue analysis using matrix-assisted laser desorption/ionization mass spectrometry: Practical aspects of sample preparation. J Mass Spectrom 38:699-708
72. Zaima N, Sasaki T, Tanaka H, Cheng XW, Onoue K, Hayasaka T, Goto-Inoue N, Enomoto H, Unno N, Kuzuya M, Setou M (2011) Imaging mass spectrometry-based histopathologic examination of atherosclerotic lesions. Atherosclerosis 217:427-432
73. Grey AC, Gelasco AK, Section J, Moreno- Rodriguez RA, Krug EL, Schey KL (2010) Molecular morphology of the chick heart visualized by MALDI imaging mass spectrometry. Anat Rec (Hoboken) 293:821-828
74. Menger RF, Stutts WL, Anbukumar DS, Bowden JA, Ford DA, Yost RA (2012) MALDI mass spectrometric imaging of cardiac tissue following myocardial infarction in a rat coronary artery ligation model. Anal Chem 84:1117-1125
75. Chughtai K, Heeren RM (2010) Mass spectrometric imaging for biomedical tissue analysis. Chem Rev 110:3237-3277
76. Seeley EH, Caprioli RM (2011) MALDI imaging mass spectrometry of human tissue: Method challenges and clinical perspectives. Trends Biotechnol 29:136-143
77. Wheelock CE, Wheelock AM, Kawashima S, Diez D, Kanehisa M, van Erk M, Kleemann R, Haeggström JZ, Goto S (2009) Systems biology approaches and pathway tools for investigating cardiovascular disease. Mol BioSyst 5:588-602
78. Ramsey SA, Gold ES, Aderem A (2010) A systems biology approach to understanding atherosclerosis. EMBO Mol Med 2:79-89
79. Jain KK (2010) Technologies for discovery of biomarkers. In: The handbook of biomarkers. Springer, New York. Jain Pharma-Biotech, Basel, Switzerland
80. Lusis AJ, Weiss JN (2010) Cardiovascular networks: Systems-based approaches to cardiovascular disease. Circulation 121:157-170
81. de la Cuesta F, Barderas MG, Calvo E, Zubiri I, Maroto AS, Darde VM, Martin-Rojas T, Gil-Dones F, Posada-Ayala M, Tejerina T, Lopez JA, Vivanco F, Alvarez-Llamas G (2012) Secretome analysis of atherosclerotic and nonatherosclerotic arteries reveals dynamic extracellular remodeling during pathogenesis. J Proteomics 75:2960-2971
82. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, Jense LJ, von Mering C (2011) The STRING database in 2011: Functional interaction networks of proteins globally integrated and scored. Nucleic Acids Res 39:D561-8